Skip to main content

10x Genomics, Inc.

TXG
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
SEC CIK
0001770787

In the last 90 days, 10x Genomics, Inc. insiders filed 0 open-market purchases and 11 sales; 393 institutions reported holding it in 13F filings for Q2 2026, worth $4.93B in total; superinvestors ARK Invest and Duquesne Family Office hold it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $12.2M in total
11
13F holdersQ2 2026, +67 vs. previous quarter
393
13F valueReported value at the end of Q2 2026
$4.93B
Superinvestors holdingAt the end of Q2 2026
2

Price chart

Superinvestors holding TXG, Q2 2026

2 superinvestors report holding 10x Genomics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

ARK Invest

Cathie Wood

2.5%

10x Genomics, Inc.'s share of the portfolio

Shares
10,003,057
Value
$383.5M

Duquesne Family Office

Stanley Druckenmiller

0.4%

10x Genomics, Inc.'s share of the portfolio

Shares
403,100
Value
$15.5M

Latest insider trades

Open-market purchases and sales by 10x Genomics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 24, 2026 (view filing)4:30 PM ETSep 222 daysSuliman ShehnaazDirectorSSaleClass A Common Stock−5.72K$81.19−$464.7K−19.4%23.8K after5 lots10b5-1
Sep 24, 2026 (view filing)4:29 PM ETSep 222 daysSaxonov SergeChief Executive OfficerSSaleClass A Common Stock−25.0K$81.22−$2.03M−2.3%1.05M after5 lots10b5-1
Sep 11, 2026 (view filing)4:47 PM ETSep 92 daysTaich AdamChief Financial OfficerSSaleClass A Common Stock−46.4K$64.57−$3.00M−12.8%316.3K after3 lots10b5-1
Sep 8, 2026 (view filing)7:00 PM ETSep 35 daysStuelpnagel John RDirectorSSaleClass A Common Stock−20.0K$61.75−$1.24M−5.7%328.4K after3 lots
Aug 28, 2026 (view filing)7:22 PM ETAug 262 daysSaxonov SergeChief Executive OfficerSSaleClass A Common Stock−10.5K$63.69−$667.9K−1.0%1.08M after3 lots10b5-1
Aug 26, 2026 (view filing)4:46 PM ETAug 242 daysSaxonov SergeChief Executive OfficerSSaleClass A Common Stock−18.5K$63.02−$1.17M−1.7%1.09M after
Aug 26, 2026 (view filing)4:44 PM ETAug 242 daysTaich AdamChief Financial OfficerSSaleClass A Common Stock−17.2K$63.02−$1.08M−4.5%362.7K after
Aug 26, 2026 (view filing)4:43 PM ETAug 242 daysHindson Benjamin J.See RemarksSSaleClass A Common Stock−13.8K$63.02−$870.9K−2.8%488.2K after
Aug 26, 2026 (view filing)4:42 PM ETAug 242 daysSuliman ShehnaazDirectorSSaleClass A Common Stock−2.21K$63.65−$140.5K−7.0%29.5K after2 lots10b5-1
Aug 17, 2026 (view filing)4:08 PM ETAug 13-144 daysTeichmann Sarah A.DirectorSSaleClass A Common Stock−7.55K$57.25−$432.3K−21.2%28.1K after2 lots10b5-1

Top 10 13F holders, Q2 2026

The largest institutional positions in 10x Genomics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 393 holders
Institutions holding TXG in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC17,629,266$675.9M0.03%−111,706−0.6%Reduced
BlackRock, Inc.10,804,070$414.2M0.01%+724,157+7.2%Added
ARK Investment Management LLCSuperinvestorARK Invest10,003,057$383.5M2.49%−1,714,260−14.6%Reduced
Vanguard Portfolio Management LLC6,982,492$267.7M0.01%+69,556+1.0%Added
Quantinno Capital Management LP5,469,698$209.7M0.25%+57,937+1.1%Added
Vanguard Capital Management LLC5,082,594$194.9M0.00%−186,992−3.5%Reduced
Price T Rowe Associates Inc4,539,007$174.0M0.02%+4,375,792+2,681.0%Added
Sumitomo Mitsui Trust Holdings, Inc.4,194,627$160.8M0.09%−915,587−17.9%Reduced
Nikko Asset Management Americas, Inc.4,192,517$160.7M2.07%−911,661−17.9%Reduced
Morgan Stanley3,351,911$128.5M0.01%+695,558+26.2%Added